In a heartfelt essay, Tatiana Schlossberg, granddaughter of JFK, shares her devastating cancer diagnosis and the impact on her family. As she battles acute myeloid leukemia, her story sheds light on both personal and political struggles.
In a groundbreaking decision, the FDA has lifted the black box warnings on hormone replacement therapy for menopause, potentially improving access for women seeking relief from menopausal symptoms.
The FDA has removed black box warnings on estrogen treatments for menopause, igniting a debate about the benefits and risks of hormone therapy. Dr. Marty Makary discusses the implications for women's health.
Exciting developments in Alzheimer's research reveal that two existing drugs may reverse brain damage in mice, offering hope for future human trials as awareness grows ahead of the Walk to End Alzheimer’s.
Diane Davis faced a devastating ovarian cancer diagnosis, but a surprising Lynch syndrome discovery and immunotherapy gave her a new lease on life. Discover her inspiring journey of resilience and hope!
Discover how a groundbreaking gene-editing technology is revolutionizing cholesterol management, potentially eliminating the need for daily medication. This breakthrough, while still in early stages, emphasizes the importance of healthy habits for heart health.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
A BBC investigation reveals that many NHS ADHD services have closed their doors to new patients, leaving countless individuals in dire need of support. With waiting times already averaging eight years, the situation is growing increasingly alarming.